JAK1
35 programs · 35 companies
Programs
35
Companies
35
Active Trials
21
Targeting JAK1
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| Ivorelsin | Eli Lilly | Approved | WilmsGBM | |
| RHH-974 | Roche | Preclinical | IPF | |
| Fixatenlimab | GSK | Phase 1/2 | DMDSLE | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | AMLOvarian Ca | |
| MLY-3531 | Mineralys | NDA/BLA | SMA | |
| Kemanesiran | Sage | Approved | CLLNB | |
| VYG-2970 | Voyager | Phase 3 | ACCLN | |
| ABC-4950 | AbCellera | Phase 2 | Bladder Ca | |
| 452-2449 | Eisai | Preclinical | SLEADHD | |
| 992-6426 | Akeso | Phase 2 | UCNarcolepsy | |
| NIA-IIT-528 | NIAID | Phase 1 | PsA | |
| CAM-IIT-818 | CAMS | Phase 1/2 | Angelman | |
| Tiracapivasertib | Lyell Immuno | Phase 2 | SMARB | |
| Mavunesiran | Fractyl | Preclinical | LGSObesity | |
| ALD-9169 | Aldeyra Ther | Preclinical | Fabry | |
| MTE-2944 | Molecular Templates | NDA/BLA | PTSD | |
| Sovaglumide | Savara | Phase 1/2 | UC | |
| Pemitinib | Shanghai Pharma | Preclinical | DLBCL | |
| ORC-7732 | Orchard (Kyowa Kirin) | Phase 3 | EoECrohn's | |
| Tezetapinarof | Tesaro (GSK) | Phase 1 | T2DNASH | |
| Nidacilimab | Aimmune | Preclinical | LGSDMD | |
| Voxafotisoran | Hugel | Phase 3 | GBMMM | |
| EVO-481 | Evommune | Preclinical | Schizophrenia | |
| FDM-9341 | 4D Molecular | Phase 2/3 | MigraineAML | |
| STA-IIT-276 | Stanford Med | Phase 3 | Migraine | |
| PLR-762 | Pliant Ther | Approved | RSVPV | |
| 051-5335 | LG Chem Life | Phase 3 | FTD | |
| MRE-7592 | Mereo BioPharma | Phase 1/2 | ObesityALL | |
| Motamavacamten | Paradigm Bio | Preclinical | PBCEpilepsy | |
| SIR-IIT-264 | Siriraj Hospital | NDA/BLA | ET | |
| KIN-IIT-763 | King Faisal Spec Hosp | Phase 1/2 | RA | |
| SCI-2060 | Scientus Pharma | Phase 2 | NarcolepsyDravet | |
| Polacapivasertib | MindMed | Approved | NBCSU | |
| CER-9073 | Certara | Phase 1 | FabryCTCL | |
| Fixatuximab | PathAI | Phase 3 | Epilepsy |